[go: up one dir, main page]

WO2017218004A1 - Aliment médical pour des patients souffrant d'une maladie hépatique chronique - Google Patents

Aliment médical pour des patients souffrant d'une maladie hépatique chronique Download PDF

Info

Publication number
WO2017218004A1
WO2017218004A1 PCT/US2016/038093 US2016038093W WO2017218004A1 WO 2017218004 A1 WO2017218004 A1 WO 2017218004A1 US 2016038093 W US2016038093 W US 2016038093W WO 2017218004 A1 WO2017218004 A1 WO 2017218004A1
Authority
WO
WIPO (PCT)
Prior art keywords
range
vitamin
cld
gsh
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/038093
Other languages
English (en)
Inventor
Michael Hudnall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/US2016/038093 priority Critical patent/WO2017218004A1/fr
Publication of WO2017218004A1 publication Critical patent/WO2017218004A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Definitions

  • the present invention relates to medical food compositions. More particularly, the present invention relates to a medical food for patients with Chronic Liver Disease specifically formulated to fulfill specific, distinctive dietary requirements of patients with chronic liver disease. In some embodiments, the medical food contemplated herein may reverse liver fibrosis.
  • CLD Chronic Liver Disease
  • HCV predominate hepatic diseases - hepatitis C
  • HBV hepatitis B
  • NAFLD non-alcoholic fatty liver disease
  • NASH non-alcoholic steatohepatitis
  • ALD alcoholic liver disease
  • All of these chronic liver conditions may lead to cirrhosis and hepatocellular carcinoma (HCC).
  • HCC cirrhosis and hepatocellular carcinoma
  • CLD has been the subject of extensive studies over the decades that add to our collective knowledge of hepatic fibrogenesis, liver disease and the various means by which CLD disrupts metabolism.
  • CS Leiber was a pioneer in these areas, performing many animal studies involving ALD, steatosis, cirrhosis and the administration of phosphatidylcholine (PC) and/or SAMe to correct CLD- associated metabolic disruptions and hepatic fibrosis.
  • PC phosphatidylcholine
  • Metabolomics involves a comparative analysis of global metabolic profiles between two or more samples. Extensive metabolomic studies have been performed on hepatobiliary diseases over the last ten years. Metabolomic studies confirmed the findings of past CLD studies documenting various disruptions of metabolism, including GSH metabolism, PC metabolism, SAMe /homocysteine metabolism, one-carbon metabolism, redox homeostasis, etc. seen in all patients with CLD.
  • Metabolomic studies have also provided new and valuable insights into CLD pathology, especially because these studies specifically identify metabolic alterations and core metabolic phenotype (CMP) changes associated with CLD.
  • CMP metabolic phenotype
  • Metabolomics involve high-throughput analytic chemistry combined with multivariate data analysis to compile an unbiased, and often extensive profile of small metabolites from various samples including animal models, in-vitro hepatocytes, live human samples, serum, plasma, etc.
  • the focus of Metabolomic studies on the liver is at least partly due to the fact that no other organ in the body has nearly as much metabolic activity as the liver, so it is an obvious choice as an organ to study changes in the metabolome associated with disease states, in this case CLD.
  • the hepatic metabolome consists of a very complex collection of small-molecule ( ⁇ 1.5kDa) lipid and water-soluble metabolites that interact in complex ways. The flux of these metabolites provides information about genomic, proteomic and transcriptomic activity that correlate with both normal and disease-altered hepatic metabolism. Extensive Metabolomic analyses on CLD samples over the last decade have identified specific metabolic/phenotypic alterations associated with various forms of hepatobiliary disease states. Not surprising, Leiber identified many of these same CLD-disrupted pathways in his many historic liver disease studies.
  • CMP Core Metabolic Phenotype
  • CMP core metabolomic phenotype
  • the CMP commences at the transition between the healthy liver (Phase 0) and NAFLD/NASH, ALD or viral hepatitis (Phase 1). This CMP is maintained in the presence or absence of cirrhosis (Phase 2) and whether or not either HCC or CCA (Phase 3) develops. Inflammatory signaling in the liver triggers the appearance of the CMP. Many other metabolomic markers distinguish between Phases 0, 1, 2 and 3.
  • a metabolic remodeling in HCC has been described but metabolomic data from all four Phases demonstrate that the Warburg shift from mitochondrial respiration to cytosolic glycolysis foreshadows HCC and may occur as early as Phase 1.
  • the metabolic remodeling also involves an upregulation of fatty acid ⁇ -oxidation, also beginning in Phase 1.
  • the storage of triglycerides in fatty liver provides high energy-yielding substrates for Phases 2 and 3 of liver pathology.”
  • CMP-associated metabolic alterations involve up-regulated biosynthetic pathways whose end-products experience greater utilization and consumption.
  • CLD-induced up-regulated biosynthetic pathways experience greater flux of metabolites, while the biosynthetic end-products of these pathways experience decreased availability or depletion due to greater utilization.
  • Increased cycling of CMP-upregulated metabolites therefore, is regarded as increased metabolic demand associated with CLD.
  • CLD causes alterations to the phenotype of the host by altering and up-regulating specific metabolic/bio synthetic pathways.
  • the combined metabolic alterations induced by CLD create increased metabolic demand and utilization for CMP-upregulated metabolites and nutrients. Increased metabolic demand translates into increased nutritional requirements for these metabolites. Therefore, increased metabolic demands associated with CMP-upregulated metabolites define the new distinctive nutritional requirements of CLD patients.
  • the term medical food as defined in section 5(b) of the Orphan Drug Act (21 U.S.C. 360ee (b) (3)) is "a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.” Therefore, what is needed is a medical food for CLD patients that supplies appropriate amounts of specific nutrients for which CLD patients experience greater demand and utilization. This medical food for CLD patients will support their new distinctive nutritional requirements.
  • the subject matter of this application may involve, in some cases, interrelated products, alternative solutions to a particular problem, and/or a plurality of different uses of a single system or article.
  • an ingestible composition may comprise N-Acetyl Cysteine in a range of 500-5,000 mg; Polyenylphosphatidylcholine in a range of 500-10,000 mg; and Alpha Lipoic Acid in a range of 200-2,500 mg.
  • This composition may be divided into individual serving sizes for administration.
  • the composition may further comprise at least one of L- Lysine; L-Arginine; Vitamin C; N-Acetyl L-Carnitine; Betaine HC1; L-Glutamate; Turmeric;
  • Proanthocyanidins Nigella sativa; Pantothenic acid; Benfotiamine; Magnesium; Vitamin E; Cynara scolymus; L-Glycine; Vitamin B l; Vitamin B2; Ubiquinol; Piper cubeba; Artemisia absinthium;
  • Vitamin B3 Vitamin B6; Zinc; Vitamin D3; Folate; Vitamin B 12; Selenium; and Biotin.
  • compositions selected to aid in a reversal of liver fibrosis may comprise N-Acetyl Cysteine in a range of 500-5,000 mg;
  • composition may be divided into individual serving sizes for administration.
  • the composition may further comprise at least one of L- Lysine; L-Arginine; Vitamin C; N- Acetyl L-Carnitine; Betaine HC1; L-Glutamate; Turmeric; Proanthocyanidins; Nigella sativa;
  • Pantothenic acid Benfotiamine; Magnesium; Vitamin E; Cynara scolymus; L-Glycine; Vitamin B l; Vitamin B2; Ubiquinol; Piper cubeba; Artemisia absinthium; Vitamin B3; Vitamin B6; Zinc; Vitamin D3; Folate; Vitamin B 12; Selenium; and Biotin.
  • Fig. 1 provides a flow chart of an embodiment of use of the medical food of the present invention.
  • the present medical food composition accomplishes the need of providing CLD patients with their new distinctive nutritional requirements.
  • the present invention is a new medical food intended to fulfill the specific dietary requirements of patients with CLD for which distinctive nutritional requirements, based on established epigenetic, metabolomic and other types of scientific research, are established.
  • composition of the present invention is referred to herein as a "medical food” or the “medical food of the present invention.” This term is intended to apply to the composition discussed for the treatment contemplated. However, it should be understood that the composition of the present invention may be used as a dietary supplement formula, as well as a drug (such as an FDA approved drug) formula.
  • the complex list of metabolites that are required to stabilize these interlinked up-regulated metabolic pathways can only be provided by a strategic and comprehensive medical food.
  • the complex balance between the medical food's numerous nutrients and the medical food's requirement of continuous administration three times per day could not be reasonably provided by simple alterations of diet alone.
  • the medical food may be administered orally in divided doses of eight capsules taken three times a day (morning, afternoon, and evening) for a total of twenty four capsules daily.
  • the formulation may also be supplied as a liquid drink, tablet, powder, gel, emulsion, micelles, liposomes, and the like.
  • CLD is not a nutrient deficiency disease like scurvy or pellagra, in which the supplementation of a particular deficient nutrient or dietary supplement may correct symptoms caused by deficiencies of a person's normal nutritional requirements.
  • ALD does not simply alter the metabolism of the patient while he is drinking. Rather the abuse of alcohol may change the patient's metabolism in the long-term and alter his nutritional requirements in ways that require fulfillment even after the patient has quit drinking.
  • the medical food is designed to address and correct the results of unfulfilled nutritional requirements in CLD patients.
  • the medical food satisfies the new distinctive nutritional requirements of CLD patients with a comprehensive list of required metabolites designed to fortify and balance all CMP interlinked and up- regulated metabolic pathways associated with patients with CLD. Research shows that these linked CMP-upregulated biosynthetic pathways experience concurrent increased demand and utilization. Therefore, a comprehensive and balanced approach is necessary in order to fulfill the new distinctive nutritional requirements of CLD patients.
  • Each medical food daily dose is split into three separate administrations in order to satisfy the constant increased nutritional requirements of CLD patients.
  • the medical food's 3x daily administration is designed to achieve optimal periods of homeostasis in CMP-disrupted systems for as long as possible throughout the day. Once or twice daily administrations of medical food will not be as effective as the present invention's three-time-daily administration, even with the same total daily amount. This is because the medical food of the present invention is designed to provide increased nutrient delivery to the cells of CLD patients in an optimal manner throughout the day, and a three-time-daily administration is necessary to achieve this purpose.
  • the medical food has identified all known metabolic pathways demonstrating CMP up- regulation in CLD. Fulfilling the new distinctive nutritional requirements for CLD patients is accomplished by supplying the necessary balanced amounts of critical nutrients and metabolites for increased flux into CMP-associated up-regulated pathways.
  • the present invention is a medical food that fulfills new distinctive nutrient requirements for patients with CLD.
  • Medical foods are not drugs and by regulation may contain only GRAS (Generally Recognized As Safe) ingredients. Every ingredient in the medical food is classified as GRAS by the FDA. Further, each ingredient in the medical food formula is in proper balance and proportion for safe administration.
  • GRAS ingredients are required to provide nutritionally balanced support for CMP up-regulated metabolic/biosynthetic/antioxidant pathways and homeostatic activity in CLD patients.
  • the medical food is not intended to treat or cure CLD. Rather, the medical food for chronic liver disease of the present invention is intended to satisfy the new distinctive nutritional requirements of CLD patients. Our intention is for the present invention's status as a medical food to be satisfied by even the FDA's narrowest interpretation of the statute. In the present clinical setting, there is evidence of a need for such a science-based medical food for CLD patients.
  • Core metabolic phenotype comprehensively identifies CLD-altered metabolic/biosynthetic pathways
  • CLD core metabolic phenotype
  • CMP core metabolic phenotype
  • Specific studies will demonstrate that the same list of CMP-associated metabolic alterations occur in each and every type of CLD.
  • the purpose of this exercise is to establish that due to the very similar nature of these CLD-induced metabolic disruptions, all patients with CLD experience the same disrupted metabolic pathways.
  • These disrupted metabolic pathways define the new distinctive nutritional requirements for patients with CLD. It is therefore appropriate to fulfill the new distinctive nutritional requirements of CLD patients by providing the same medical food formula, because the medical food of the present invention addresses the same disrupted metabolic pathways present in every form of CLD, regardless of the etiology.
  • the medical food accomplishes this by providing a balanced and comprehensive medical food formula with scientific justification and upcoming human clinical trials.
  • CMP is associated with the following global changes in the metabolome of CLD patients:
  • Part A CMP-associated metabolic changes listed above combine to create extreme oxidative stress, which the evidence has been well documented in all CLD. Therefore, as stated above, the rest of Part A will be dedicated to establishing the new CMP-associated distinctive nutritional requirements of CLD patients. The discussion about how to fulfill the new distinctive nutritional requirements of CLD patients will take place in Part B, below.
  • CMP is associated with disruption of phospholipid, cholesterol and bile acid homeostasis
  • PC Phosphatidylcholine
  • CMP-associated changes in the lipidome of CLD patients It has long been known that lipid metabolism experiences widespread disruption in patients with CLD and that these metabolic changes are associated with distinct changes in specific metabolic biomarkers. Of particular interest to metabolomic researchers has been CMP-associated disruption of PC homeostasis. It has been demonstrated in a variety of studies that all types of CLD patients experience decreased PC availability due to increased utilization and/or impaired synthesis in patients with CLD.
  • CLD-associated CMP changes cause elevated levels of cholesterol and bile acids. Increased cholesterol infiltration of the mitochondrial membrane has been associated with mitochondrial GSH depletion. Bile acids are created from cholesterol and bile acids are found elevated in patients with CLD.
  • Glycochenodeoxycholic acid is the main toxic component of bile acid and elevated GCDCA has been shown to be significantly associated with decreased mitofusin 2 (Mfn2) gene expression. Decreased Mfn2 is associated with many mitochondrial-related diseases. This was demonstrated in a study conducted by Chen et al in which normal human hepatocytes induced by GCDCA showed significant decreased in Mfn2 activity resulting in mitochondrial damage. However, this mitochondrial damage was reversed in the lab by stimulating overexpression of Mfn2.
  • NAFLD Non-Alcoholic Fatty Liver Disease
  • NAFLD exhibits CMP-associated disruption of PC biosynthetic pathways.
  • a study comparing human steatotic livers versus non-steatotic livers showed elevated PC metabolites in steatotic livers, indicating increased activity in the PC biosynthetic pathway.
  • Another research study documented rodents who were fed diets that induced fatty liver experienced up-regulated utilization of PC, choline, betaine, and trimethylamine N-oxide.
  • Other human and animal studies have shown PC disruption in NAFLD.
  • NAFLD causes an increase in lipid species in the liver and serum/plasma, including cholesterol esters and various bile salts.
  • NAFLD is marked by less hepatic inflammation, and therefore less bile acids disruption than NASH,
  • NASH Non-Alcoholic Steatohepatitis
  • NASH is defined as advanced- stage NAFLD accompanied by high inflammatory activity. As much as 67%-80% of NAFLD patients may remain as benign fatty liver with minimal progression to cirrhosis and normal mortality rates compared to the general population. However, approximately 20%- 33% of NAFLD patients may progress to NASH.
  • NAFLD fatty liver
  • Lysophosphatidylcholine acyltransferases which convert LPC to PC were up-regulated in NASH with a 200%-400% increase in hepatic LPCATl, LPCAT2, and LPCAT3 mRNAs.
  • LPCAT Lysophosphatidylcholine acyltransferases
  • the inflammatory component of NASH may be linked to fatty acids transported to the liver from visceral adipose.
  • NASH-associated inflammation is also linked to bile acid disruption in the liver.
  • Gonzalez et al suggested "...the decline in serum LPC and rise in serum bile acids are a signature of the inflammatory component of NASH, rather than the steatotic component.”
  • ALD Alcoholic Liver Disease
  • ALD has long been implicated in disrupted PC metabolism.
  • a study on cirrhotic patients reported that whether cirrhosis was due to alcohol or HBV, there was a decrease in serum LPC of cirrhotic patients compared to healthy volunteers. Animal studies have shown that alcohol exposure may produce pathologies that correlate with NASH.
  • a study on alcoholic micropigs initially showed increased hepatic triglycerides, and then after six months demonstrated inflammation, steatosis and fibrosis. The authors concluded that increased lipid synthesis and reduced LPC synthesis and export were responsible for the accumulation of hepatic triglycerides in ALD.
  • the findings showed the mice developed a mild hepatic hemorrhage and serum PC was elevated. There was a decrease in saturated and
  • Metabolomic ALD studies show that ALD-induced cirrhosis is associated with higher bile acids and lower LPCs (92,94) in a manner almost identical with non-alcoholic and HBV-induced cirrhosis. Id. HBV and HCV - PC, cholesterol and bile acid homeostasis
  • PC biosynthesis is known to be disrupted in both HCV and HBV.
  • a Metabolomic study in China studied HBV patients with deteriorating liver function demonstrated disrupted PC levels. The study describes decreased PC species combined with an elevation of toxic bile acids, glycochenodeoxycholic acid (GCDCA).
  • GCDCA glycochenodeoxycholic acid
  • Another Chinese study reported similar results when examining the progression of chronic HBV to cirrhosis. The same phenomena are also seen in NALFD/NASH, cirrhosis and HCC.
  • HCV disrupts many aspects of lipid metabolism. Lipids are necessary for HCV viral assembly and secretion. HCV replication modulates host cell lipid metabolism dramatically to enhance its replication. The HCV life cycle requires numerous lipids, which have been shown to be essential modulators of the HCV viral lifecycle.
  • HCV disrupts cholesterol metabolism by causing proteolytic cleavage of sterol regulatory element binding proteins (SREBPs), thereby inducing steatosis.
  • SREBPs sterol regulatory element binding proteins
  • Bile acids are derived from cholesterol and HCV disrupts bile acid metabolism as well as cholesterol metabolism.
  • Apolipoprotein and VLDL synthesis is altered in HCV and HCV-infected hepatocytes showed increased production of cholesterol and sphingolipids, both of which HCV utilizes to aid in virion maturation and infectivity.
  • Cholesterol-depleted or sphingomyelin-hydrolysed virus had a negative impact on infectivity.
  • Metabolomic analysis of HCV-infected hepatocytes showed a significant increase in cholesterol and various sphingoid bases.
  • HCV-infected tree shrews which showed increased bile acids and decreased PC availability; both are hallmarks of CLD-induced CPM alterations.
  • HBV, HCV, and NASH all trigger similar metabolomics alterations involving hepatic inflammation-mediated changes to bile acid metabolism. Serum bile acids have been found to be higher in patients with severe fibrosis as compared to patients with moderate fibrosis.
  • HCV HCV-infected human hepatocytes
  • VLDL production and secretion which in turn may add to the accumulation of hepatic triglycerides due to decreased VLDL packaging of triglycerides for hepatic export.
  • GCDCA GCDCA levels, one of the main toxic components of bile acids, in HBV-infected patients. Serum bile acids have also been found to be elevated in HCV patients. As mentioned previously, Mitofusin2 (Mfn2) gene expression regulates mitochondrial morphology and signaling. A recent study showed that one of the signature toxic components of bile acids, GCDCA, decreases the expression of Mfn2.
  • GDCDA exacerbates extreme oxidative stress by negatively affecting Mfn2 gene expression. Therefore, disruption of PC availability affects the GSH pathway, and all linked up-regulated CMP pathways contribute to extreme oxidative stress, which is the hallmark of CLD.
  • CMP is associated with increased storage of cytosolic triacylglycerides (TGL) in fatty liver and altered ⁇ -oxidation of fatty acids (FA)
  • Visceral adipose supplies fatty acids to the liver for ⁇ -oxidation.
  • PC catabolism is also considered a source of fatty acids for hepatic ⁇ -oxidation.
  • visceral adipose known for being highly inflammatory, may be responsible for exporting the inflammatory component which distinguishes NAFLD from the inflammatory state of NASH.
  • both visceral adipose and up-regulated PC metabolism are considered sources of hepatic fatty acids associated with increased hepatic triacylglycerols.
  • Increased catabolism of PC by phospholipases Al and A2 in the liver release free fatty acids.
  • These free fatty acids require ⁇ -oxidation in the mitochondria of hepatocytes.
  • Un-oxidized fatty acids are repackaged as hepatic triacylglycerols, creating NAFLD and setting the stage for NASH.
  • NAFLD is considered to be the physical manifestation of metabolic syndrome in the liver. Metabolomic studies have found increased lipid species triacylglycerides and diacylglcerides in both liver and blood samples of NAFLD patients.
  • Non-Alcoholic Steatohepatitis NASH
  • TGL Triacylglycerides
  • FA Fatty Acids
  • NAFLD and NASH are both characterized by changes in the cellular lipid profile.
  • NASH is NAFLD with a major inflammatory component.
  • researchers have been searching for the cause of NASH-associated hepatic inflammation, and new studies theorize that adipose tissue, which is intrinsically pro-inflammatory, may be the origin of hepatic inflammation.
  • Lipidomic studies show similar significant lipid metabolic disruption in both NASH and NAFLD with only small differences in three PC species to distinguish the two.
  • triacylglycerols and several fatty acids were shown to be elevated in plasma, while various other fatty acids showed decreased levels in plasma.
  • Other studies also showed that NASH patients with cirrhosis show reduced cellular carnitine levels, which may negatively affect ⁇ -oxidation of fatty acids in the mitochondria.
  • ALD Alcoholic Liver Disease
  • TGL Triacylglycerides
  • Fatty Acids FA
  • Leiber found a correlation with ethanol intake and the accumulation of hepatic fatty acids and triglycerides. Leiber also showed that ethanol has extreme effects on lipid peroxidation. Metabolomic studies suggest that hepatic fatty acids and triacylglycerides increase and plasma fatty acids and PC species decrease in ALD.
  • visceral adipose is also a source for both hepatic fatty acids and hepatic triacylglycerols.
  • the HCV-infected tree shrew study (Tupaia belangeri chinensis) suggested that HCV causes alterations in carnitine esters and fatty acids.
  • HCV patients have been shown to have low levels of carnitine species, which impairs ⁇ - oxidation of fatty acids.
  • An extensive metabolomics study on HCV-infected hepatocytes showed that HCV infection causes an increase in lipid content within hepatocytes, or liver steatosis.
  • Steatosis is the accumulation of intracellular fatty acids in the liver, and it has been associated with HCV infection, increased oxidative stress and progression to liver cirrhosis.
  • HCV causes proteolytic cleavage of sterol regulatory element binding proteins (SREBPs), thereby increasing cholesterol and inducing steatosis.
  • SREBPs sterol regulatory element binding proteins
  • HCV-infected hepatocytes A metabolomic analysis of HCV-infected hepatocytes showed that HCV disrupts fatty acid ⁇ -oxidation and fatty acid transport to the mitochondria. The study also showed that HCV-infected hepatocytes have an increase in fatty acid concentration and a decrease in mediators of fatty acid transport. Acyl-carnitine (necessary for fatty acid transport to the
  • CMP is associated with a shift from aerobic respiration to anaerobic glycolysis (Warburg shift)
  • Insulin resistance is associated with NAFLD/NASH.
  • NAFLD/NASH In mice, insulin is reported to activate pyruvate kinase M2, which is the enzyme that triggers cytosolic glycolysis involved in the Warburg shift.
  • the shift from aerobic respiration to anaerobic glycolysis results in the production of lactate and alanine from pyruvate.
  • the Warburg shift occurs as early as Phase 1 in NAFLD/NASH progression. 3c.
  • ALD - Warburg shift ALD progresses towards a shift in aerobic respiration to anaerobic glycolysis along the parallel path of fibrosis/cirrhosis, CMP expression and HCC development.
  • HCV has been found to shift metabolism from aerobic respiration towards the pentose phosphate pathway.
  • the pentose phosphate pathway is a parallel pathway with anaerobic glycolysis.
  • the pentose phosphate pathway creates NADPH and five-carbon sugars, which are then oxidized by glycolysis in HCV patients.
  • CMP is associated with GSH depletion, increased consumption of thiol-containing metabolites, extreme oxidative stress and altered one-carbon metabolism
  • CLD of all etiologies are associated with CMP-induced hepatic extreme oxidative stress.
  • Glutathione is the master controller of cellular redox status, maintaining and regulating the redox status of cellular enzymatic and non-enzymatic (small-molecule) antioxidants.
  • CLD-associated depletion of GSH may cause depletion of all linked cellular antioxidants that are normally maintained and regulated by GSH.
  • NAFLD samples Metabolomic analyses on a variety of types of NAFLD samples have been performed on animal models, living human subjects and human tissue samples.
  • NAFLD steatosis
  • NASH steatohepatitis
  • mGSH mitochondrial glutathione
  • MCD methionine and choline deficient diet
  • GSH or SAMe therapy restored GSH in the mitochondria and ameliorated hepatocellular injury in mice fed either a MCD or MD diet.
  • Alcohol toxicity has also long been linked to folate/homocysteine or one-carbon metabolism disruption.
  • Early research established significant ethanol-associated glutathione depletion and oxidative stress, altered methionine metabolism, altered folate/homocysteine/one-carbon metabolism,
  • Changes in gene expression can be accomplished through alterations in DNA coding sequence. Changes in gene expression and phenotype may also be caused by other mechanisms.
  • Epigenetics is the study of these heritable changes. DNA can be modified epigenetically by DNA methylation, histone modifications, and RNA-based mechanisms. Recent studies have focused on epigenetic features, transcriptional factors and signaling pathways associated with chronic ALD. These new studies provide greater nuanced perspectives of ALD/CLD disease pathology. Consumption of ethanol causes epigenetic changes (CMP) that contribute to ALD. In an extensive study, ethanol affected metabolism of methionine and thereby DNA methylation.
  • CMP epigenetic changes
  • ALD is associated with GSH depletion in the mitochondria. Studies show that ALD-induced mitochondrial GSH depletion is associated with cholesterol-enrichment of the mitochondrial membrane, which leads to impairment of GSH transport of cytosolic GSH into the mitochondria in both ALD and NAFLD/NASH.
  • HCV and HBV induce hepatic oxidative stress.
  • the mechanisms for increasing oxidative stress in both pathologies are well known. These mechanisms involve epigenetic changes caused by viral proteins interacting with both mitochondria and endoplasmic reticulum (ER) to increase mitochondrial reactive oxygen species (ROS) generation.
  • HCV core expression inhibits electron transport at Complex I, and increase Complex I ROS production. They also induce depletion of mitochondrial GSH, increase mitochondrial membrane permeability and impair various antioxidant defense mechanisms.
  • HCV-mediated mitochondrial disruption is a causative factor in GSH depletion and the creation of extreme oxidative stress.
  • HCV has been shown to create replication sites in the mitochondrial membrane that damages mitochondrial form and function.
  • HCV has also been shown to disrupt the GSH metabolic pathway, causing greater utilization of GSH and disrupted biosynthesis.
  • HCV-impaired GSH biosynthesis contributes to a large increase in ROS generation that further contributes to mitochondrial GSH depletion.
  • CLD causes extreme oxidative stress as a result of CMP-associated metabolic disruptions and unfulfilled distinctive nutritional requirements.
  • NASH, ALD, HCV, and HBV all have been associated with extreme oxidative stress.
  • CLD-induced metabolic changes increase ROS and NOS levels, which disrupt redox homeostasis and create extreme oxidative stress.
  • Depletion of GSH results in the inability to counteract oxidative-mediated insults to cellular systems, resulting in irreversible cellular degeneration and cell death.
  • GSH depletion and CLD-associated oxidative stress may damage mitochondria form and function.
  • non-enzymatic small molecule antioxidants and antioxidant minerals are both depleted as a result of CLD-induced oxidative stress, GSH depletion and cirrhosis.
  • GSH is the main regulator of cellular redox homeostasis and redox signal transduction. Under normal metabolism, cellular redox status is maintained and regulated by the glutathione redox couple GSH:GSSG (GSSG is an oxidized form of GSH), along with the NADPH/NADP+ and Trx-SH/Trx-SS redox couples. Redox balance is involved in cellular signal transduction, and small changes in the GSH:GSSG ratio are involved in the fine-tuning of signal transduction in physiological events such as cell cycle regulation and other processes.
  • Protein-S-glutathionylation is an important mechanism for post-translational regulation of a large list of regulatory, structural and metabolic proteins that play roles in cell signaling and metabolic pathways. Protein-S-glutathionylation production requires a reactive cysteinyl residue, present at physiological pH in the thiolate form. Under oxidative stress, these cysteinyl residues may be oxidized and react with GSH leading to a glutathionylated-cysteine derivative. Both GSSG and S- glutathionylated proteins may be catalytically reduced back to GSH, while they both may also be reduced back to GSH non-enzymatically.
  • Protein-S-glutathionylation is an important mechanism for post-translational regulation.
  • GSH-controlled cellular redox homeostasis increases oxidative stress. Disruption of GSH homeostasis has been implicated in the pathogenesis and progression of many human diseases.
  • GSH is also critically involved in mediating the susceptibility of nitric oxide (NO) and NO derivatives in the body.
  • GSH is involved in countering Reactive Nitrogen Species (RNS) associated oxidative stress and counteracting RNS-mediated damage.
  • RNS Reactive Nitrogen Species
  • CLD increases ROS and NO levels, which disrupt redox homeostasis and create extreme oxidative stress.
  • depletion of GSH results in the inability to counteract oxidative stress and NO-mediated insults to hepatic cellular systems, resulting in irreversible cellular degeneration and cell death.
  • Hepatic fibrogenesis involves a process whereby CMP-associated oxidative stress triggers the conversion of normally quiescent hepatic stellate cells into active collagen- secreting myofibroblasts.
  • Part B The medical food contemplated herein fulfills the new distinctive nutritional requirements for patients with CLD
  • Part A we established that all forms of CLD create distinctive epigenetic changes in the phenotype and alterations of metabolism in patients with CLD. We also established that these changes are similar, and in most cases identical in all forms of CLD, regardless of the disease etiology.
  • CMP Core Metabolic Phenotype
  • CMP phenotypic changes are very similar in all CLD, whether they involve epigenetic changes and/or metabolic alterations associated with chronic ALD, NAFLD, NASH or oncogenic viruses like HCV or HBV.
  • CMP-associated changes result in the up-regulation of specific biosynthetic metabolic pathways, which increases the metabolic demand for metabolites and end-products involved in those biosynthetic pathways.
  • a person's complete nutritional requirements are defined as the sum of a person's combined metabolic demands. Therefore the new distinctive nutritional requirements of CLD patients must factor in increased demand for metabolites and end-products of up-regulated biosynthetic pathways associated with CLD.
  • CLD/CMP-altered biosynthetic pathways are interlinked and most of these up-regulated pathways draw directly on SAMe stores. These interlinked pathways include the GSH and PC pathways as well as the
  • Fibrogenesis involves the conversion of hepatic stellate cells into myofibroblasts. Myofibroblasts secrete collagen into the extracellular spaces of the liver, resulting in fibrosis and cirrhosis.
  • liver fibrosis was once considered irreversible, modern studies have demonstrated that once the trigger to fibrogenesis (extreme oxidative stress) is switched off, myofibroblasts apoptosis may occur while hepatic stellate cells remain quiescent and the process of collagen resorption may then proceed at a fairly constant rate. The process of collagen resorption is well established and has been demonstrated in numerous animal and human CLD studies.
  • SAMe is the most ready methyl donor of all the one-carbon methylation donors, so it is no surprise that all CMP up-regulated biosynthetic pathways similarly draw on SAMe. SAMe is also involved in the transsulfuration pathway in GSH synthesis. Further, there is a large body of existing current and historical studies involving exactly these same CMP metabolic pathway alterations and the interlinked effects that one altered pathway may have on other CMP pathways. Dr. C.S. Leiber was a pioneer in this area and performed a series of seminal studies on ALD and liver cirrhosis.
  • CMP alterations establish a vicious positive feedback loop regarding CLD-induced oxidative stress: CMP-altered metabolic pathways create extreme oxidative stress, and extreme oxidative stress negatively affects the altered CMP metabolic pathways.
  • Extreme oxidative stress causes increased oxidation of: PC to oxidized PC; methionine to methionine sulfate; homocysteine to homocystine; cysteine to cystine; GSH to GSSG. , GCDCA in bile acid, and proteins to PrS-SC, PrS-SG, and PrS- SCG.
  • These oxidized metabolites require reduction to reactivate their healthy roles in metabolism. Accumulation of oxidized forms of these metabolites may have negative implications for health. For instance, oxidized PC may cause apoptosis in macrophages and affect cell viability.
  • PC supplementation has also been studied in CLD, as has SAMe supplementation. While animal studies have shown promise, human studies targeting individual metabolites have been inadequately controlled and have shown mainly inconclusive results. There have been calls for human clinical trials involving combinations of these CLD up-regulated metabolites.
  • the medical food clinical trials will demonstrate that its treatment serves to decrease oxidative stress and/or re-establish redox homeostasis in study patients. This in turn will down-regulate fibrogenic activity and slow down or stop the progression of fibrosis while allowing the reversal of fibrosis to occur.
  • This reversal of liver fibrosis is a primary and unexpected advantageous result of the present invention. Reports of reversal of fibrosis in ALD patients who have quit drinking vary and have been inconsistent, while there has been a dearth of studies regarding this topic. Therefore, clinical trials of the present invention will determine if and/or when reversal of fibrosis is possible in non-drinking, compliant patients with ALD.
  • the medical food clinical trials will investigate whether the fibrogenic activity associated with CLD may be down-regulated by fulfilling the distinctive nutritional requirements of CLD patients, and furthermore, whether reversal of fibrosis may be accomplished even in the presence of continuing CLD in the cases of HCV, HBV and NAFLD/NASH patients or in the chronically altered phenotype of non-drinking, compliant ALD patients.
  • the medical food clinical trials will monitor changes in liver fibrosis staging in CLD patients over time. Any positive improvement in fibrosis staging may be due to down-regulation of the fibrogenic activation caused by fulfillment of the distinctive nutritional requirements of the CLD patients. Conversely, any additional progression of fibrosis may be associated with the direct action of CLD rather than unfulfilled nutritional requirements of the CLD patients.
  • Dr. Leiber was responsible for many important discoveries including the microsomal ethanol oxidizing system (MEOS) involving cytochrome P4502E1. Dr. Leiber performed many important animal studies involving PC and SAMe administration in ALD. Early on, Dr. Leiber noted that PC supplementation decreased oxidative stress, correctly observing that supplying the biosynthetic end- product of the PC biosynthetic pathway decreases draw on SAMe, which is then re-directed to GSH biosynthesis. Dr. Lieber observed that the resulting up-regulation in GSH production was responsible for the observed decrease in oxidative stress.
  • MEOS microsomal ethanol oxidizing system
  • Dr. Leiber went on to study PC and SAMe administration in rats and baboons fed ethanol, noting that PC administration attenuated CC14 and ethanol-induced liver injury, while SAMe restored hepatic GSH levels and had a positive effect on mitochondrial lesions and leakage.
  • Dr. Leiber pointed to promising animal studies and called for human studies involving administration of SAMe to patients with ALD, noting that "...therapeutic administration of SAMe should be the subject of a comprehensive clinical trial to assess its capacity to attenuate early stages of alcoholic liver injury in human beings.”
  • the immediate metabolic precursor of SAMe is methionine, but methionine must be enzymatically activated to SAMe, and this enzyme is impaired in ALD. Therefore, he warned against administering methionine instead of SAMe due to this enzymatic inhibition, "The precursor of SAMe is methionine, one of the essential amino acids, which is activated by SAMe- synthetase (EC 2.5.1.6). Unfortunately, the activity of this enzyme is significantly decreased as a consequence of liver disease. Because of decreased utilization, methionine accumulates and, simultaneously, there is a decrease in SAMe that acquires the status of an essential nutrient and therefore must be provided exogenously as a super nutrient to compensate for its deficiency.”
  • Dr. Leiber studied SAMe depletion in early ALD and noted that decreased SAMe levels occur even before SAMe-synthetase is inhibited. Dr. Leiber attributed SAMe depletion to extreme oxidative stress associated with the metabolism of alcohol, which rapidly consumes GSH. Because SAMe is one of the rate-limiting steps in GSH biosynthesis, exogenous SAMe administration was an object of many studies by Dr. Leiber on patients with ALD, and his conclusions all favored human clinical trials involving SAMe and PC administration in patients with CLD.
  • the present invention does not include SAMe as a required metabolite in its formula.
  • the medical food compensates for this omission in three ways:
  • SAMe contributes four major benefits in CLD; further, increased GSH production by SAMe is generally regarded as the most significant benefit.
  • GSH biosynthetic pathway S-adenosylmethionine (SAMe) and N-acetylcysteine (NAC).
  • SAMe S-adenosylmethionine
  • NAC N-acetylcysteine
  • administration of either SAMe or NAC will promote GSH production.
  • the medical food of the present invention chooses to fulfill the distinctive metabolic requirements of the CMP-associated up-regulated GSH pathway by providing NAC as the rate-limiting metabolite instead of SAMe to stabilize the GSH pathway and to increase GSH synthesis.
  • NAC safely and effectively increases GSH production without affecting the SAM/SAH/methionine pathway; thereby fulfilling CMP-increased metabolic demand for GSH metabolites while simultaneously saving SAMe for other uses including proper DNA methylation.
  • proper GSH bioavailability will work to reduce CMP-associated oxidative stress and CLD metabolic perturbations associated with extreme oxidative stress.
  • the medical food phase II human clinical trials will administer CMP-associated metabolites in a comprehensive and systematic approach to fulfill up-regulated CMP metabolic demand with proper levels of required metabolites.
  • the medical food clinical trials will examine the effects of this regimen using FibroScan, a non- invasive device, to assess liver stiffness, which correlates well with fibrosis staging in patients with CLD.
  • the medical food does not treat CLD - it will not cure or treat HCV, HBV, NASH or ALD; rather it satisfies the new distinctive nutritional requirements of patients with CLD.
  • Extreme oxidative stress is created in CLD in part as a result of unfulfilled nutritional requirements of patients. Fulfilling the distinctive nutritional requirements of CLD patients may therefore decrease oxidative stress. If long- term re-establishment of redox homeostasis may be achieved, then improvement in fibrosis staging may be possible. This is because fibrogenesis is not a direct action of CLD. Fibrogenesis is a separate hepatic process that is triggered by extreme oxidative stress associated with CLD, but fibrosis is not caused by any direct action of CLD.
  • CLD-associated extreme oxidative stress is at least in part the result of unfulfilled metabolic requirements of patients with CLD, resulting in decreased availability or depletion of necessary metabolites of the PC, GSH, SAMe, and one-carbon metabolic pathways. Extreme oxidative stress is associated with the trigger to fibrosis generation; therefore if redox homeostasis is reestablished, down-regulation of the fibrogenic process may be achieved.
  • the medical food of the present invention's intended use is to re-establish redox homeostasis by fulfilling the metabolic/nutritional demands of the CLD patients. Studies have shown that once the fibrogenic activity is eliminated, resorption of hepatic collagen may then occur thereby decreasing fibrosis staging.
  • the present medical food invention fulfills the new distinctive nutritional requirements of CLD patients
  • Glutathione (GSH) in the body is intrinsically involved with cellular redox homeostasis, and therefore GSH homeostasis is important in any disease that causes increased levels of oxidative stress.
  • extreme oxidative stress is a hallmark of CLD and GSH is depleted due to decreased production and overconsumption.
  • GSH is essential for cellular redox homeostasis and GSH synthesis is tightly regulated in the cytosol. After synthesis, GSH is distributed to intracellular compartments such as the mitochondrial membrane, endoplasmic reticulum and the nucleus. It is also exported to extracellular spaces including the blood and bile for utilization by other tissues. The half-life of GSH is only 2-3 hours. GSH is only catabolized in the extracellular space by gamma-glutamyl transferase (GGT). The gamma glutamyl cycle involves the rapid catabolism of extracellular GSH into constituent peptides, which are then quickly taken back up by the cells for rapid re-synthesis into GSH.
  • GTT gamma-glutamyl transferase
  • This gamma glutamyl cycle of GSH cellular export/catabolism/re-uptake/re-synthesis may be energy inefficient, but it is a perfect design for a rapid-response antioxidant system in response to extreme oxidative challenges.
  • Intracellular GSH status depends on precursor availability, the rate of GSH oxidation to GSSG, and the capacity to recycle GSSG back to GSH at the expense of NADPH. Under normal physiological conditions, reduced GSH levels are 10 to 100 times greater than oxidized GSH (GSSG) and mixed disulphide (GSSR).
  • the ratio of reduced and oxidized forms of GSH is important in cell signaling, maintaining redox homeostasis and the promotion of cellular mechanisms associated with cell proliferation, cell differentiation or apoptosis, while small variations in GSH:GSSG ratio tightly regulate redox signaling.
  • GSH depletion has been associated with inhibition of cytochrome c oxidase (CcOX) activity, microtubule network disassembly, and processes associated with NO toxicity.
  • CcOX cytochrome c oxidase
  • GSH biosynthesis GSH is produced through the transsulfuration pathway involving SAMe conversion (cycling) to homocysteine, then to NAC.
  • NAC and L-Glutamate are then combined into gamma-glutamylcysteine by the enzyme gamma-glutamyl synthetase - the rate-limiting step in the biosynthesis of GSH.
  • Glycine is then added to the C terminal of the gamma-glutamylcysteine molecule by the action of the enzyme glutathione synthetase.
  • CMP-associated oxidative stress induced by CLD increases GSH activity and consumption, which in turn prompts changes in GSH levels.
  • CLD creates a distinctive nutritional requirement for increased GSH production.
  • GSH is depleted in CLD, causing demand for greater synthesis and flux of SAMe and other GSH metabolites through the GSH pathway.
  • GSH depletion has been shown to be involved in hepatic stellate cell activation in fibrogenesis.
  • GSH performs a variety of metabolic roles in the body, including antioxidant functions as a radical scavenger and as a redox signaling modulator. GSH scavenges free radical ROS and RNS directly and indirectly through enzymatic reactions. GSH also reacts enzymatically with
  • GSH selenium-dependent Glutathione Peroxidase
  • GSH may also reduce and detoxify ROS -promoted lipid-oxidation products such as malonyl dialdehyde and 4-hydroxy- 2-nonenal, as well as many other species.
  • GSH maintains thiol homeostasis of cysteine residues on proteins. It also conjugates and stores cysteine reserves.
  • Glutathione is associated with estrogen, leukotriene, and prostaglandin metabolism. GSH also participates in the production of
  • deoxyribonucleotides in the maturation of iron-sulfur cluster in proteins, and it participates in signal transduction and cellular transcription.
  • NAC NAC to increase GSH production rather than SAMe.
  • Administration of NAC has also long been known to safely promote intracellular GSH production, decrease oxidative stress and has had anti-fibrotic actions in preliminary human studies.
  • NAC has also been shown to decrease inflammatory markers and decrease hepatic fatty acid accumulation in ethanol-fed rats.
  • the addition of NAC to corticosteroids has also been shown to decrease hepatorenal syndrome, infection, and short-term mortality in patients with severe ALD.
  • the medical food supplies NAC for GSH synthesis, which decreases demand for SAMe because SAMe is normally converted to NAC for GSH synthesis.
  • the present invention also provides PC, which also decreases SAMe utilization in the PC PEMT biosynthetic pathway in CLD.
  • Administration of NAC and PC both of which are metabolic end-products of CMP-disrupted metabolic pathways, conserve SAMe for other purposes, including DNA methylation or some of the many other metabolic functions of SAMe.
  • CLD is associated with DNA hypomethylation.
  • DNA hypomethylation results in phenotypic and epigenetic alterations.
  • ALD causes alcoholic steatosis and methionine metabolism disruption associated with DNA hypomethylation and altered gene expression.
  • SAMe is one of the main one-carbon methyl donors that methylates DNA.
  • SAMe availability is limited by impaired enzyme activity in the SAM/SAH/methionine cycle in ALD patients, and decreased SAMe is one of the causes of DNA hypomethylation.
  • the medical food restores SAMe availability by administering all of the one-carbon methyl donors associated with CMP pathways, as well as by saving SAMe from overutilization in the GSH and PC pathways. In this way, the medical food's one-carbon metabolites safely restore enzymatic cycling of the homocysteine/SAH/methionine pathway to produce more SAMe for proper DNA methylation.
  • CLD is also characterized by increased mitochondrial permeability transition, and this is associated with ROS penetration into the cytosol.
  • NAC has been shown to inhibit alterations of mitochondrial permeability transition. Therefore, metabolic precursors of the GSH biosynthetic pathway including NAC, glycine, and glutamate are the distinctive required nutrients for patients with CLD.
  • the present invention supplies metabolites involved in other GSH-interlinked antioxidant systems
  • GSH biosynthesis is intrinsically involved in the regulation and redox cycling of various antioxidant systems.
  • CMP up-regulated thiol-containing antioxidant systems need dietary management to fulfill their functions and remain in homeostasis, and the medical food supplies NAC, ALA and PC to fulfill the distinctive nutritional requirement of CLD patients for these up-regulated thiols.
  • the body has two basic antioxidant systems, classified as the enzymatic antioxidant system and the non-enzymatic antioxidant system: • Enzymatic antioxidants include superoxide dismutase (SOD), catalase, glutathione peroxidase, thioredoxin and glutaredoxin.
  • SOD superoxide dismutase
  • catalase catalase
  • glutathione peroxidase glutathione peroxidase
  • thioredoxin glutaredoxin
  • Small molecule non-enzymatic antioxidants include lipid-soluble vitamins A, D and E.
  • Vitamins B, C and GSH are water-soluble antioxidants.
  • GSH is the master controller for proper cooperative reduction of these linked-chain small molecule non-enzymatic cellular antioxidants.
  • Intracellular small molecule antioxidants like vitamins B's, C, D and E are consumed at an increased rate due to CLD-associated extreme oxidative stress.
  • trace elements like zinc, selenium, and manganese are metabolic antioxidant cofactors that also experience greater utilization in patients with CLD.
  • Selenium is a cofactor of glutathione peroxidase, and zinc, manganese and copper are cofactors for SOD.
  • antioxidants require reduction after oxidation in order to re-establish antioxidant function. This is accomplished through reducing systems such as glutathione/glutathione disulfide, dihydrolipoate/lipoate, or NADPH/NADP+ and NADH/NAD+. These small molecule antioxidants also reduce each other in a linked-chain re-charging redox system. For instance, CoQIO has been shown to enhance enzymatic NADH- and NADPH- recycling of tocopherols in mitochondria without being consumed itself. Vitamin C, ALA and GSH all reduce vitamin E . Vitamin E reduces vitamin A and the carotenoids, while it stabilizes membranes and protects against lipid peroxidation. ALA and selenium reduce GSH.
  • GSH reduces cystine, vitamin C and polyphenols.
  • Decreased levels of GSH and increased oxidative stress associated with CLD have an impact on the reduction capacity of the small-molecule non-enzymatic antioxidant system, while chronic extreme oxidative stress may impair the ability of the redox system to maintain cellular redox homeostasis.
  • Due to the interlinked nature of their redox duties depletion of any individual members of this cellular non-enzymatic small-molecule antioxidant recharging system may result in decreased levels of all members of this linked antioxidant system. For these reasons, proper combinations of linked antioxidants are required for full-system stabilization.
  • GSH also contributes to the redox homeostasis of mitochondrial antioxidant metabolites, including the B vitamin family, CoQIO and ALA.
  • Antioxidant minerals such as zinc, selenium and magnesium are consumed at a higher rate in CLD related to increased oxidative stress.
  • ALD has also been shown to impair zinc uptake. Therefore, CLD creates a distinct nutritional requirement for increased intake of these antioxidant mineral metabolites.
  • Zinc, selenium and magnesium are part of the required nutrients contained in the medical food to meet increased demand from CLD-associated elevation of oxidative stress.
  • the medical food contemplated herein provides the full complement of interlinked small- molecule non-enzymatic antioxidants, including the antioxidant minerals zinc, selenium, magnesium, CoQIO, vitamins A, B, C, D, E, and the thiol-based cellular antioxidant ALA in moderate, balanced quantities.
  • the medical food's three times-daily administration schedule is intended to maximize periods of nutrient delivery in response to the constant up-regulated metabolic and nutritional demands of patients with CLD.
  • the medical food nutrients also fulfill a distinctive nutritional requirement for B vitamins, which are necessary for proper mitochondrial metabolism, and which are altered in CLD.
  • Vitamin B deficiencies cause mitochondrial dysfunction, and administration of B vitamins may ameliorate symptoms associated with B vitamins deficiencies and prevent mitochondrial toxicity.
  • the medical food fulfills a distinctive nutritional requirement for all the B vitamins in patients with CLD. This distinctive nutritional requirement is due to increased consumption due to CLD- associated extreme oxidative stress.
  • Niacin (vitamin B3) is a necessary mitochondrial B vitamin and is the precursor of NAD and NADPH.
  • Niacin supplementation has a positive effect on fatty liver.
  • a study by Li et al found "Chronic EtOH feeding induced significant lipid accumulation in the liver, which was ...ameliorated by dietary NA supplementation. Liver total NAD, NAD(+), and NADH levels were remarkably higher in the NA supplemented group than the NA deficient or EtOH alone groups”.
  • NADH reduces oxidized GSH.
  • the medical food supplies thiamine (vitamin B l), another mitochondrial antioxidant B vitamin found decreased in CLD. Thiamine administration reversed many of the detrimental effects of ethanol administration in rats.
  • CoQIO is a mitochondrial antioxidant and involved in electron transport in the mitochondria. Intracellular CoQIO levels reflect the functional status of the electron transport complex in the mitochondria. CoQIO reduces GSH without being consumed itself due to its promotion of enzymatic process.
  • the medical food formula fulfills the distinctive nutritional requirements for vitamin E, selenium, magnesium and zinc, which are depleted in CLD, in particular HCV infection. Studies demonstrated administration of these antioxidants alleviated symptoms of oxidative stress in patients with HCV.
  • the medical food also fulfills a distinctive nutritional requirement for magnesium. Magnesium deficiency is associated with cirrhosis and it plays a significant role in increasing oxidative stress and apoptosis, as well as accelerating the aging process.
  • Zinc has long been known to have antioxidant functions. As noted above, various studies found selenium and zinc at low levels in CLD and HCV- infected patients.
  • Zinc and selenium were also found to be decreased in liver cirrhosis patients, and administration of zinc and selenium had positive metabolic effects on cirrhotic and cancer patients.
  • Vitamin E and selenium were found to promote hepatic stellate cell apoptosis in rats.
  • Selenium has long been known for its antioxidant effects, and studies show that selenium appears to cause up-regulation of manganese superoxide dismutase (MnSOD).
  • MnSOD manganese superoxide dismutase
  • Selenium is also involved in the thioredoxin and glutaredoxin thiol-based enzymatic antioxidant systems. Vitamin E and selenium supplied together have been found to decrease hepatic stellate cell activation and hepatic fibrosis.
  • Vitamin D is a metabolic antioxidant, and it is known to be deficient in all CLD, in particular NAFLD and HCV .
  • the medical food nutrients fulfill a distinctive nutritional requirement for Vitamin D in CLD patients.
  • the medical food nutrients fulfill a distinctive nutritional requirement for alpha lipoic acid (ALA), which is a cellular thiol-containing antioxidant.
  • ALA alpha lipoic acid
  • ALA can lower oxidative stress and it plays an essential role in mitochondrial antioxidant reactions, quenching ROS such as
  • ALA also reduces vitamin C and GSH, which in turn recycles vitamin E.
  • ALA fulfills a
  • ALA promotes GSH synthesis and vitamin C levels, and modulates transcription factors like NFkappaB.
  • ALA has dramatic effects in oxidative stress conditions. L-carnitine and ALA reversed mitochondrial oxidative damage and serum liver enzymes in NASH model mice. Further, ALA chelates metal ions like iron and
  • ALA is an important constituent of the linked-chain intracellular antioxidant system and it is known to have potent redox properties, but evidence shows that besides being a direct scavenger of oxidants, ALA has been shown to stimulate GSH synthesis through an up-regulation of a transcription factor, Nrf2. Nrf2 determines the expression of antioxidant and detoxification genes regulated by the antioxidant response element (ARE). Significantly, ALA has also been shown to modulate NF-kappaB transcription factor activity, which is involved in hepatic stellate cell activation.
  • CLD-induced oxidative stress establishes the distinctive nutritional requirement for thiol- containing antioxidants as well as non-enzymatic small molecule cellular antioxidants, of which ALA is both.
  • the medical food protocol provides moderate amounts of ALA to fulfill the distinctive nutritional requirements of CLD patients.
  • the medical food of the present invention supplies Botanical Polyphenols - integral components of the body's physiological antioxidant response
  • the medical food provides polyphenols from GRAS botanicals due to the new distinctive nutritional requirements of CLD patients and their CMP-associated disruption of redox system homeostasis and inducement of extreme oxidative stress.
  • Polyphenols from GRAS botanicals are important integral components of the body's normal metabolic response to oxidative stress. Studies have shown that botanical polyphenols prevent Nrf2 translocation and modulate NF-kappaB pathways, thereby protect DNA from oxidative stress-mediated damage. Dietary botanical polyphenols are integral components of our bodies' physiological antioxidant response. Administration of botanical polyphenols and other antioxidant metabolites have been shown to be helpful in liver disease due to their metabolic antioxidant effects.
  • the medical food provides the following GRAS botanicals whose administration in animal and human studies on CMP-associated oxidative stress have been demonstrated:
  • Artimisia absinthia (wormwood) has been shown to prevent chemically induced liver damage in animal models. Artimisia has also been shown to be hepatoprotective in ethanol-induced hep ato toxicity in animal models and antifibrotic in CC14 induced fibrosis in animal models. Artimisia inhibited the inflammatory response induced by lipopolysaccharides by preventing NF-kappaB activation in human hepatoma cells and rat livers.
  • Piper cubeba (cubeb berries) has been used in folk medicine for centuries. It contains monoterpenes and sesquiterpenes among its phenolic components while also providing micronutrients. Piper also contains piperine, which has been associated with antioxidant efficacy, inhibition of liver fibrosis and hypolipidic effects in high-fat diet rats. Piperine has also been shown to inhibit the macrophage inflammatory response. Cynara scolymus (artichoke) has been shown to reduce hepatic oxidative stress and restore lipoprotein homeostasis in rats fed a high cholesterol diet. Polyphenols from artichoke have been shown to markedly reduce hepatic oxidative stress in rats and to prevent the loss of GSH in rat hepatocytes. Further, artichoke was found to inhibit cholesterol biosynthesis in rat hepatocytes. As seen in Part A, cholesterol levels increase in patients with CLD due to CMP-associated metabolic changes.
  • Nigella sativa (black cumin) administration to HCV patients in Egypt was found to be
  • Black cumin seeds and oils have been found to be hepatoprotective against hepatotoxicity induced by either disease or chemicals. The beneficial effects are likely related to their cytoprotective and metabolic antioxidant actions. In lipopolysaccharide-induced inflammation, black cumin has an antioxidant effect. Black cumin has also been shown to have beneficial
  • Curcuma longa has been found to have significant hepatic antioxidant properties in ethanol-induced oxidative stress, in rabbits fed an atherogenic diet, and in liver oxidative damage induced by lead acetate in mice.
  • Turmeric extract (curcumin) has been found to inhibit the progression of liver cirrhosis in thiocetamide induced liver cirrhosis in rats.
  • Turmeric extract was also found to regulate plasma cholesterol and fatty liver in rats fed a high-cholesterol diet.
  • Turmeric exerts an antioxidative effect on phospholipid peroxidation and hepatic lipid metabolism in mice fed a high cholesterol or atherogenic diet.
  • Curcumin has long been shown to be an effective antioxidant nutrient in liver diseases. Further, Curcumin inhibits several factors like nuclear factor NF-kappaB, a prototypical proinflammatory signaling pathway. Curcumin attenuates liver injury induced by ethanol,
  • Curcumin has been shown to be hepatoprotective against ethanol-induced hepatic fibrosis by inhibiting hepatic stellate cell proliferation and by suppressing TGF-Beta signaling.
  • Grape Seed extract has been shown to reduce oxidative stress in experimental animal biliary obstruction studies, in methotrexate induced oxidative stress in rat liver, in radiation induced oxidative stress in rat liver, and in a rat model of diabetes mellitus, which is a condition that aggravates CLD. Grape Seed extract has also been shown to improve liver function in patients with NAFLD.
  • the medical food of the present invention supplies phosphatidylcholine (PC), which fulfills a distinctive nutritional requirement for increased PC in chronic liver disease patients
  • PC is a main cellular membrane phosphoplipid, and it is associated with proper cell membrane and mitochondrial membrane form and function.
  • PC is synthesized in two different biosynthetic pathways in the body. These include the SAMe dependent PEMT pathway and CDP-choline pathway.
  • SAMe is involved in three successive methylations of phosphatidylethanolamine (PE) to form PC.
  • the PEMT pathway occurs in the liver only.
  • the other main PC biosynthetic pathway is called the CDP-choline pathway (or the Kennedy pathway) and it occurs in the rest of the cells of the body. In this pathway, PC is created through conversion of dietary choline into CDP-choline and then to PC.
  • CLD causes decreased availability of PC, and oxidation of PC in membranes can occur in CLD due to extreme oxidative stress. It has been shown that CLD creates increased demand for PC and choline.
  • the medical food supplies PC, the biosynthetic end-product of both PC pathways.
  • PC administration spares SAMe from increased flux into the PEMT PC pathway.
  • PC administration also produces choline, which is produced from the catabolism of PC.
  • Both dietary choline and PC-derived choline are either cycled back to the CDP-choline pathway for PC production or cycled to the production of betaine, a necessary one-carbon donor involved in the SAM/SAH/methionine metabolism, or also to acetylcholine.
  • NAC has been shown to decrease oxidative stress in alcoholic hepatitis and in cirrhosis animal studies .
  • PC administration by itself has shown an anti-fibrogenic effect in studies performed on patients with CLD.
  • a European PC clinical study found reduced levels of procollagen-III- peptide in HBV patients, while a study on HCV patients found decreased levels of albumin-bound hydroxyproline.
  • anti-fibrotic improvement in histology was shown in pharmacological and clinical studies performed on patients and animals administered PC.
  • the medical food of the present invention supplies metabolites of the SAM/SAH/methionine cycles, which experience greater utilization by chronic liver disease patients
  • SAMe has positive effects on oxidative stress in CLD, increasing GSH levels, which are depleted in CLD. It is known that SAMe may play an important role in
  • Methionine/homocysteine metabolism and choline metabolism are interdependent.
  • acetylcholine and betaine Feeding a diet deficient in choline and methionine has been used as a mechanism to create steatosis in the lab for studies. As noted previously, all of these CLD- affected pathways are linked to SAM/SAH/methionine and GSH metabolism, and therefore
  • nutritional deficiencies in any of these pathways may contribute to oxidative stress.
  • the medical food of the present invention supplies metabolites of one-carbon methyl metabolism
  • the medical food formula also includes one-carbon methyl donors such as folate, vitamin B 12, vitamin B6 and betaine. Increased SAM/SAH/methionine cycling creates greater demand for one- carbon methylation factors. These one-carbon metabolites are distinctive required nutrients provided in the medical food protocol for their one-carbon methyl donating properties and their interlinked duties with the SAM/SAH/methionine cycle and the homocysteine/NAC/GSH cycle, both of which experience greater utilization in patients with CLD.
  • one-carbon methyl donors such as folate, vitamin B 12, vitamin B6 and betaine.
  • Increased SAM/SAH/methionine cycling creates greater demand for one- carbon methylation factors.
  • These one-carbon metabolites are distinctive required nutrients provided in the medical food protocol for their one-carbon methyl donating properties and their interlinked duties with the SAM/SAH/methionine cycle and the homocysteine/NAC/GSH cycle, both of which experience greater utilization in patients with CLD.
  • One-carbon methyl donors like folate, vitamin B 12 and betaine convert homocysteine to methionine, and vitamin B6 directs homocysteine to NAC, which is then ultimately converted to GSH.
  • Proper methylation by these one-carbon methyl donors is important to avoid accumulation of homocysteine in the body. Therefore, any up-regulation of the SAM/SAH/methionine cycle must necessarily be accompanied by increased utilization of these critical one-carbon methyl donors.
  • Betaine one of a necessary medical food metabolites, aids in the conversion of homocysteine to methionine. Betaine is also a thiol-enhancing cofactor.
  • One-carbon methyl donors have positive nutritional effects on redox homeostasis and oxidative stress due to their intrinsic role in SAM/SAH/methionine metabolism.
  • the medical food does not provide SAMe or methionine to satisfy the distinctive nutritional requirement of CLD patients for increased SAMe. Rather, the medical food concentrates on saving SAMe by decreasing the draw of SAMe into the other highly up-regulated CMP pathways, the PC and GSH pathways.
  • SAMe- homocysteine-methionine cycling is impaired due to decreased enzymatic activity, which the medical food restores by administering one-carbon metabolic methyl donors like betaine, which protects against ethanol-induce fatty liver infiltration in ALD.
  • Betaine' s restorative power to disrupted ALD metabolic pathways is generally attributed to its role in restoring SAMe supplies and thereby decreasing oxidative stress.
  • a study conducted by Yung et al documented that betaine' s hepatoprotective activity is associated with its effects on sulfur amino acid metabolism.
  • the medical food of the present invention supplies metabolites of CLD depleted amino acid
  • CLD increases utilization and decreases availability of L-Carnitine.
  • L-Carnitine levels are diminished in all CLD, in particular HCV, and this makes it a required metabolite in the medical food formula.
  • Depletion of L-Carnitine may have negative effects on CLD-associated steatosis because L- Carnitine transports cytosolic fatty acids to the mitochondria for ⁇ -oxidation.
  • ⁇ -oxidation of fatty acids is another CMP up-regulated activity.
  • the medical food supplies L-lysine, which combines with methionine to form the CMP-depleted amino acid, L-Carnitine.
  • the medical food also supplies L- Carnitine to meet increased demands for increased ⁇ -oxidation of fatty acids in patients with CLD.
  • L-Carnitine prevents progression of NASH in a mouse model by up-regulating the mitochondrial ⁇ -oxidation and redox system.
  • L-Carnitine and ALA reversed mitochondrial oxidative damage and serum liver enzymes in NASH mouse model.
  • the medical food also supplies arginine as a required amino acid metabolite in CLD patients.
  • Arginine is oxidized to form nitric oxide (NO). NO is involved in the modulation of hepatic
  • Arginine administration selectively increases NO levels, which improves hepatic microcirculation and tissue oxygenation in patients with cirrhosis.
  • a study conducted by Nanji et al reported that "...our results show that arginine administration, probably through the generation of nitric oxide, leads to improvement in pathological changes such as fatty liver, necrosis, inflammation, and fibrosis. These improvements were accompanied by down-regulation of nuclear factor NF- ⁇ , pro-inflammatory cytokines cyclooxygenase-2, and inducible nitric oxide synthase".
  • GSH depletion leads to NO toxicity, so the medical food contemplated herein supplies the GSH metabolites, NAC, L-glutamate and L-lysine for GSH production.
  • the medical food supplies arginine as a necessary amino acid metabolite for patients with CLD. Decreased arginine levels may be associated with hepatic encephalopathy and hyperammonemia due to urea cycle disruption. Studies have found that the CMP-associated metabolic disruption of the of the ammonia detoxification pathway " ...precede the histological manifestation of irreversible liver damage". Arginine administration must be balanced with lysine administration, which is also present in the medical food formula. Lysine is also a metabolic precursor of L-carnitine, as mentioned above.
  • a daily dose of the medical food contemplated herein may comprise the following ingredients in the following mass ranges:
  • N-Acetyl Cysteine in a range of 500-5,000 mg
  • Vitamin C as ascorbic acid & calcium ascorbate
  • Turmeric (Curcuma longa) in a range of 200-1,500 mg
  • Grape seed extract (95% Proanthocyanidins) in a range of 100-1,000 mg
  • Black cumin seed (Nigella sativa) in a range of 50-400 mg
  • Pantothenic acid (as calcium pantothenate) in a range of 20-10,000 mg
  • Magnesium (as magnesium citrate) in a range of 50-800 mg
  • Vitamin E as mixed tocopherols in a range of 50-1,000 IU
  • Vitamin B 1 in a range of 10-200 mg Vitamin B2 in a range of 10-200 mg
  • CoQIO as ubiquinol
  • Cubeb berries (Piper cubeba) in a range of 10-100 mg
  • Vitamin B3 in a range of 45-3,000 mg
  • Vitamin B6 (as pyridoxine HC1) in a range of 10-200 mg
  • Zinc as zinc citrate in a range of 5-50 mg
  • Vitamin D3 in a range of 400-10,000 IU
  • Folate (as folic acid) in a range of 200-3,000 meg
  • Vitamin B 12 (as methylcobalamin in a range of 200-3,000 meg
  • the present medical food may not have all of the above listed components. Indeed many may be omitted.
  • any combination of N- Acetyl Cysteine, Alpha Lipoic Acid, Polyenylphosphatidylcholine, and one or more of the above listed components may constitute the medical food of the present invention.
  • the medical food the composition may comprise Acetyl Cysteine, Alpha Lipoic Acid, Polyenylpho sphatidylcholine .
  • a flow chart of an embodiment of use of the medical food of the present invention is provided.
  • a patient having chronic liver disease is identified.
  • This patient is then provided with a three times daily regimen of an embodiment of the medical food.
  • the medical food may be taken in any number of manners, as noted above.
  • the patient may be tested to track progress and efficacy. This testing may involve periodic blood tests and liver stiffness measurement using a noninvasive medical device called FibroScan. Based on the changes measured and caused by the medical food regimen, it may be adjusted, continued, or the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur un aliment médical. L'aliment médical est configuré, de façon précise, pour ceux qui souffrent d'une maladie hépatique chronique de sorte à répondre aux besoins nutritionnels spécifiques provoqués par la maladie hépatique chronique. Dans certains cas, l'aliment médical de la présente invention peut permettre une inversion de la fibrose hépatique. Selon un mode de réalisation, l'aliment médical est configuré de sorte à être administré sous forme de capsule mais peut être administré de toute autre manière consommable sans s'écarter de la portée de l'invention.
PCT/US2016/038093 2016-06-17 2016-06-17 Aliment médical pour des patients souffrant d'une maladie hépatique chronique Ceased WO2017218004A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2016/038093 WO2017218004A1 (fr) 2016-06-17 2016-06-17 Aliment médical pour des patients souffrant d'une maladie hépatique chronique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/038093 WO2017218004A1 (fr) 2016-06-17 2016-06-17 Aliment médical pour des patients souffrant d'une maladie hépatique chronique

Publications (1)

Publication Number Publication Date
WO2017218004A1 true WO2017218004A1 (fr) 2017-12-21

Family

ID=60663324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/038093 Ceased WO2017218004A1 (fr) 2016-06-17 2016-06-17 Aliment médical pour des patients souffrant d'une maladie hépatique chronique

Country Status (1)

Country Link
WO (1) WO2017218004A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021184807A1 (fr) * 2020-03-16 2021-09-23 Wuhan Vast Conduct Science Foundation Co., Ltd. Agrégats de cuivre, composition et procédé de traitement de la cirrhose du foie
WO2023091173A1 (fr) * 2021-11-16 2023-05-25 Michael Hudnall Procédés de traitement de maladies hépatiques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028356A2 (fr) * 1999-10-18 2001-04-26 Muscletech Research And Development Inc. Complement alimentaire destine a augmenter la masse maigre et la resistance de celle-ci
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink
WO2016015634A1 (fr) * 2014-07-29 2016-02-04 Shenzhen Hightide Biopharmaceutical, Ltd. Sels de berbérine, sels ursodésoxycholiques et des combinaisons, des procédés de préparation et d'application correspondants
US20160058713A1 (en) * 2014-09-02 2016-03-03 Bhupinder Singh Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028356A2 (fr) * 1999-10-18 2001-04-26 Muscletech Research And Development Inc. Complement alimentaire destine a augmenter la masse maigre et la resistance de celle-ci
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink
WO2016015634A1 (fr) * 2014-07-29 2016-02-04 Shenzhen Hightide Biopharmaceutical, Ltd. Sels de berbérine, sels ursodésoxycholiques et des combinaisons, des procédés de préparation et d'application correspondants
US20160058713A1 (en) * 2014-09-02 2016-03-03 Bhupinder Singh Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021184807A1 (fr) * 2020-03-16 2021-09-23 Wuhan Vast Conduct Science Foundation Co., Ltd. Agrégats de cuivre, composition et procédé de traitement de la cirrhose du foie
WO2023091173A1 (fr) * 2021-11-16 2023-05-25 Michael Hudnall Procédés de traitement de maladies hépatiques

Similar Documents

Publication Publication Date Title
US11252984B2 (en) Methods of liver disease treatment
Wesselink et al. Feeding mitochondria: Potential role of nutritional components to improve critical illness convalescence
Figueroa-Soto et al. Glycine betaine rather than acting only as an osmolyte also plays a role as regulator in cellular metabolism
Steed et al. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia
Yin et al. l‐Cysteine metabolism and its nutritional implications
Zhou et al. Serine alleviates oxidative stress via supporting glutathione synthesis and methionine cycle in mice
Kharbanda Alcoholic liver disease and methionine metabolism
McLeay et al. Dietary thiols in exercise: oxidative stress defence, exercise performance, and adaptation
Depeint et al. Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism
Stanger et al. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium.
US8202512B2 (en) Metabolic uncoupling therapy
Mani et al. A critical life-supporting role for cystathionine γ-lyase in the absence of dietary cysteine supply
Lieber S-Adenosyl-L-methionine and alcoholic liver disease in animal models: implications for early intervention in human beings
US20020182196A1 (en) Composition and method for normalizing impaired or deteriorating neurological function
Kim et al. Alleviation of acute ethanol-induced liver injury and impaired metabolomics of S-containing substances by betaine supplementation
Sun et al. Mitochondrial nutrients stimulate performance and mitochondrial biogenesis in exhaustively exercised rats
Goncharov et al. Nutraceuticals in sports activities and fatigue
Mandelker Introduction to oxidative stress and mitochondrial dysfunction
Small et al. Oxidative stress and antioxidant therapy in chronic kidney and cardiovascular disease
Gonzalez et al. Mitochondrial correction: a new therapeutic paradigm for cancer and degenerative diseases
Berger Do micronutrient deficiencies contribute to mitochondrial failure in critical illness?
Zesiewicz et al. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status
Schiliro et al. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells 2021, 10, 1056
Schalinske Interrelationship between diabetes and homocysteine metabolism: hormonal regulation of cystathionine [beta]-synthase
WO2023091173A1 (fr) Procédés de traitement de maladies hépatiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16905657

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 18/04/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 16905657

Country of ref document: EP

Kind code of ref document: A1